Pharma M&A Forecast Sunny

Sunny with little chance of rain: Pharma M&A forecast

Pharma M&A activity is hot out the blocks for the first quarter, with activity in the Pharma, Medical & Biotech sector totaling $63.4 billion, higher than its 2013 counterpart at $14.2 billion.   On 9th April Mergermarket released its Global Q1 2014  Pharma, Medical & Biotech M&A Trend Report,  identifying large scale growth in the pharmaceutical sector, compared to last year. …

Download Presentation: Facilitating External Collaborations through Regional Licensing & Acquisitions

At the last BioPharma Asia in 2013, Dr Phil Kearney of Merck Sharp and Dohme gave the following presentation entitled: Facilitating External Collaborations through Regional Licensing & Acquisitions. Click here to download this presentation. The presentation covered: Merck’s strategy changes to strengthen licensing & Acquisition Pharma’s current challenges/opportunities Overview of Merck’s licensing processes and partnering opportunities MINT (Merck Initiative for …

#Amgen strengthens their portfolio with the acquisition of KAI Pharmaceuticals

Amgen announced today an agreement with KAI Pharmaceuticals, a privately owned company based in San Francisco, in which they will pay $315 million in cash to acquire KAI. Under this agreement Amgen will have worldwide rights (excluding Japan) to KAI Pharmaceuticals lead product candidate KAI-4169. KAI-4169 is a novel agent currently being studied for the treatment of secondary hyperparathyroidism in …